Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report

[1]  S. Pol,et al.  Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. , 2016, Annals of the rheumatic diseases.

[2]  M. Imamura,et al.  Improvement of renal dysfunction in a patient with hepatitis C virus‐related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  R. Chung,et al.  Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents , 2016, Hepatology.

[4]  R. Chung,et al.  Treatment of Hepatitis C Virus-Associated Mixed Cryoglobulinemia with Sofosbuvir-Based Direct-Acting Antiviral Agents. , 2015 .

[5]  Y. Karino,et al.  High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms , 2015, Advances in Therapy.

[6]  K. Chayama,et al.  Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.

[7]  P. Messa,et al.  Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  S. Brodsky,et al.  Infection-related glomerulonephritis. , 2011, Contributions to nephrology.

[9]  D. Landau,et al.  Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? , 2007, Annals of the rheumatic diseases.

[10]  M. Jadoul,et al.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease , 2008 .

[11]  L. Quartuccio,et al.  Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. , 2006, Rheumatology.

[12]  J. Piette,et al.  Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  G. Panarello,et al.  Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. , 2000, Digestive and Liver Disease.

[14]  C. Alpers,et al.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  D. Gretch,et al.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-α , 1995 .

[16]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[17]  C. Alpers,et al.  Renal manifestations of hepatitis C virus infection. , 1994, Kidney international.

[18]  R. Rodby,et al.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. , 1993, Journal of the American Society of Nephrology : JASN.